Proactive Investors - Run By Investors For Investors

Breakfast Alert - WideCells Group, Gordon Dadds Group, SimiGon

Breakfast Alert - WideCells Group, Gordon Dadds Group, SimiGon

Set menu

AIM:

Total number of AIM Companies (Incl Susp):

955*

Total number of AIM Companies trading:

906*

*as at close of business  12 February 2018

 

Standard List**  of Main Market:

Total number of Standard List Companies

 (Incl Susp):

 136

 

Total number of Standard List Companies trading:

122*

*as at close of business  12 February 2018

 

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):

86*

 

Total number of NEX Growth Market Companies trading:

82*               

*as at close of business 12February 2018

                                *A corporate client of Hybridan LLP

**  Standard Listing as defined by Hybridan LLP to be a business with strictly  operational activity

                                       

Dish of the day

Rockrose Energy readmitted (LON:RRE) readmitted to standard list following RTO of  Idemitsu Group.  Idemitsu UK's assets comprise, inter alia, a substantial number of producing fields in the North Sea . Market cap c £19.8m

 

Off the menu   

Red Leopard—RLH delisted under AIM rule 14. Potential RTO may see a new IPO in due course.

                               

What’s cooking in the IPO kitchen?

AIM

GRC International Group— holding company for a group of companies providing a range of products and services to address the IT governance, risk management and compliance requirements of organisations. Offer TBC, expected 5 March 2018

Core Industrial REIT—established to invest in Irish-based industrial properties, predominantly located in the Greater Dublin Area . Vendor placing and new funds to a total of €225m, Target gross proceeds €207m.

TruFin—holding company of an operating group comprising three growth-focused FinTech and banking businesses operating in three niche lending markets: supply chain finance, invoice finance and dynamic discounting. Offer raising £70m at 190p with market cap of £185m, expected 21 Feb

Polarean  - The medical drug-device combination companies operating in the high resolution medical imaging market. Offer TBC. Due 22 Feb

Block Energy—a  NEX Listed UK based oil exploration and production company whose main country of operation is the Republic of Georgia, looks to join AIM end of February 2018. Offer TBC

 

Main Market Specialist Funds

Life Settlement—closed-ended investment company whose principal activities will be to support and manage portfolios of whole and partial interests in life settlement policies issued by life insurance companies operating predominantly in the US.  Due 6 Mar.

 

Main Market Premium Listing

Energean Oil & Gas—Seeking gross proceeds of c.$500m. Independent oil and gas exploration and production company focused on  exploration, development and production of assets in the Eastern Mediterranean . Due march 2018.

IntegraFin provides platform services to UK clients and their financial advisers through its award-winning platform, Transact. Due Mar 18. FYSep2017 PBT up 44% to £29.9m.

 GEMS Education—report by Reuters that the private schools group is seeking a $4.5bn to $5bn London float in 2018. FYAug17 rev $926.2m and adjusted EBITDA $261.6m.

 CVC (Sky Bet) rumoured to be seeking £2.5bn plus float.

 VC firm Augmentum rumoured to be seeking raise up to £125m.

                        

Breakfast buffet

WideCells Group (LON:WDC) 13.4p £8.7m

The healthcare services group focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is pleased to announce a number of corporate developments.

David Henriques has been appointed to the board as a NED:

* Mr Henriques has significant asset management and corporate finance experience, and is involved with the digitalisation of insurance products

* Wideacademy, the Group's 100% owned education and training division, has successfully launched the first stage of www.wideacademy.

co -  Provides educational content for both the public and medical professionals to raise the profile of stem cell technologies and support the development of the industry.

* Platform combines free-to-access educational areas with paid for premium digital tools and resources for doctors/medical professionals.

We could see no forecasts.

 

Gordon Dadds Group (LON:GOR) 171.9p £49.16m

“The acquisitive legal and professional services business, is pleased to announce that it has completed the acquisition of Cardiff solicitors, Thomas Simon Limited for £1.88m plus an amount related to net tangible assets.”

 Thomas Simon is a well-established law firm whose main business areas are property (predominantly commercial), corporate, dispute resolution, private client and family.  For the year ended 31 July 2016, Thomas Simon achieved unaudited profit before tax of £0.43m on fee income of £2.09m.

Gordon Dadds recently moved its central Cardiff client facing business into new modern offices in anticipation of further expansion. Thomas Simon's business will be merged with Gordon Dadds' business in the new offices. The support functions for Thomas Simon's business enhance the Group's back office capacity and will be merged with Gordon Dadds' own support functions. FYMar18E rev £ 30.6m, £5.39m PBT.

 

SimiGon (LON:SIM) 15.25p £7.84m

The specialist “in modelling, simulation and training solutions, is pleased to announce that it has received a prime contract with the US Federal Aviation Administration (FAA) to deliver the Company's SIMbox simulation software, SIMbox simulation development tools, and engineering services for the FAA's Advanced Unmanned Aircraft System Research Simulator ("AURS").

This is a follow-on order from the original contract announced in September 2017 and is worth approximately $120,000 and has been factored into management's expectations for fiscal year 2018.”

 The AURS supports human factors research and safety research within the FAA's Aerospace Human Factors Research Division. SIMbox delivers the user interface for the operators in an aircraft simulation environment as well as a central repository for all components with the embedded configuration management capability.

We could see no forecasts.

 

Frontier IP (LON:FIPP) 83.5p £31.96m

“Completion of a first fundraising for portfolio company Molendotech Limited. Molendotech has received a commitment totalling £0.5m which will be invested in three tranches. Frontier IP will hold approximately 14% of the issued share capital of Molendotech following the investment of the third tranche. Molendotech develops a novel test which is able to identify the concentration of faecal bacteria in water. Molendotech's rapid, point-of-use test to determine water quality enables more informed decision-making about the use of water and significantly improves the ability to identify and track any pollution source.” Gaining commercial tractions.

 

Europa Oil & Gas (LON:EOG) 3.97p £11.97m

“Europa Oil & Gas, the UK and Ireland focused exploration, development and production company, is pleased to note a draft decision advertisement issued by the Environment Agency on 15 February (http:// bit.ly/2C3rPDh) that it is inclined to award a bespoke environmental permit for drilling and testing the Holmwood exploration well in PEDL 143 at Bury Hill Wood, Coldharbour Lane, Surrey. Further information can be found on the Environment Agency website http:// bit.ly/2Eu00ph.

A four-week public consultation process runs from 15 February to 15 March 2018. The Environment Agency issued a press release on 16 February 2018 regarding the consultation process. For further information, follow this link: http:// bit.ly/2Buoa05.”

 

Directa Plus (LON:DCTA) 50.5p £22.33m

The producer and supplier of graphene-based products for use in consumer and industrial markets, announces that the Ufficio Brevetti e Marchi (Italian Patent and Trademark Office) has granted the Company a patent for the product and application of its new graphene-based solution for enhancing the performance of tyres. Specifically, the patent covers Directa Plus' 'elastomeric composition comprising graphene and tyre components comprising said composition'.

The incorporation of Graphene Plus (G+) in tyres produces the joint effect of simultaneously reducing rolling resistance and increasing grip. The result is a tyre that is both faster in motion and safer in turning under braking or in extreme weather conditions.”

 

Next Fifteen Communications (LON:NFC) 421p £318.5m

“Next 15, the digital communications group, is pleased to announce a trading update ahead of its results for the year ended 31 Jan 2018, which are due to be announced in early April 2018. Next 15 anticipates that the results will be in line with the Board's expectations and the Board expects the Group to make further good progress in the year ahead.

The Group has seen an improvement in organic revenue growth in the second half of the financial year with organic revenue growth compared with the second half of last year expected to be in the high single digits. This comes off the back of the expansion of existing clients such as Samsung and the addition of Slack and Nike as significant new customers.” FY Jan 18E rev £198.8m, PBT £29.6m.

 

Diurnal Group (LON:DNL) 176.5p £92.8m

“The specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces a marketing and distribution agreement with Emerge Health Pty Ltd (Emerge Health), a leading, specialised Australian pharmaceutical company focused on the marketing and sales of niche, high quality medicines to the hospital sector. The agreement covers the commercialisation of Diurnal's novel therapies, Alkindi® (hydrocortisone granules in capsules for opening) and Chronocort®­(modified release hydrocortisone), in Australia and New Zealand.” Potential Australian approval in 2020.

 

MedaPhor Group (LON:MED) 12.25p £11.1m

“The intelligent ultrasound software and simulation company, announces the launch of its new BodyWorks Eve simulator platform, an ultra-realistic manikin-based simulator to train medical professionals practising Point-of-Care Ultrasound (PoCUS) across emergency medicine and critical care.

First revealed at the International Meeting on Simulation in Healthcare (IMSH) in Los Angeles last month and now launched for general sale, the BodyWorks Eve is believed to be the first hi-fidelity female manikin-based simulator for emergency PoCUS training.”

 

 

 

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute “independent investment research” for the purposes of the Financial Conduct Authority rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the Financial Conduct Authority) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the Financial Conduct Authority).

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use